CMS issues billing code for Lymphoseek
Article Thumbnail ImageAugust 21, 2013 -- The U.S. Centers for Medicare and Medicaid Services (CMS) has issued a billing code for the Lymphoseek radiopharmaceutical from Navidea Biopharmaceuticals.

To get access to this article and all of the content on, create a free account or sign-in now.

Member Sign In:
MemberID or E-mail Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
using your social networking account:
using your social networking

CMS issued a pass-through C-code under the Healthcare Common Procedure Coding System (HCPCS), which Navidea believes will streamline billing and reimbursement for healthcare providers using the product, a technetium-99m agent for lymphatic mapping. Navidea believes the billing code will become effective on October 1.

Lymphoseek was approved by the U.S. Food and Drug Administration (FDA) in March to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.